|
Sign In to gain access to subscriptions and/or personal tools.
|
Patients' and Physicians' Interpretations of Graphic Data Displays
Dennis J. Mazur, MD, PhD
David H. Hickam, MD, MPH
To assess how patients' and physicians' treatment preferences are influenced by graphic data displays (five-year survival curves), a cross-sectional survey of patients, physicians, and medical students was done in a university-based Department of Veterans Affairs Medical Center. Participants in the study were 119 patients seen in a general medicine clinic, 43 physicians, and 67 medical students. Three five-year survival graphs were used. Each graph contained survival curves for two alternative unidentified treatments for an unidentified med ical condition. Graph 1 was a baseline graph used in previous studies of framing effects. Graph 2 contained one survival curve having an area under the curve that was 24% greater than that in graph 1. Graph 3 contained one survival curve that had an area under the curve that was 42% greater than that in graph 1. Respondents were asked to indicate which treatment they preferred for each graph and which aspects of the five-year survival curves most influenced their choices. Respondents did not receive numerical data about the dif ference between the areas under the two curves. Most patients did not change their pref erences across the three graphs. A significantly larger (p 0.0001) proportion of physicians and medical students than of patients changed their preferences across the three graphs. Patients appeared to use information contained in five-year survival graphs in a different way than physicians and medical students, minimizing or neglecting the importance of ele ments of the five-year survival curve other than immediate (year 0) and long-term (year 5) survival data when presented with curve areas of differing sizes, while the physicians reported using intermediate (year 2 to year 4) data as well as curve shape. Key words: cognitive biases; framing effect; informed consent; medical decision making; preference; five-year survival; life expectancy. (Med Decis Making 1993;13:59-63)
Medical Decision Making, Vol. 13, No. 1,
59-63 (1993)
DOI: 10.1177/0272989X9301300108

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al.
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction
J. Clin. Oncol.,
July 1, 2009;
27(19):
3235 - 3258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Ancker and D. Kaufman
Rethinking Health Numeracy: A Multidisciplinary Literature Review
J. Am. Med. Inform. Assoc.,
November 1, 2007;
14(6):
713 - 721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Zikmund-Fisher, D. M. Smith, P. A. Ubel, and A. Fagerlin
Validation of the Subjective Numeracy Scale: Effects of Low Numeracy on Comprehension of Risk Communications and Utility Elicitations
Med Decis Making,
October 1, 2007;
27(5):
663 - 671.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Ancker, Y. Senathirajah, R. Kukafka, and J. B. Starren
Design Features of Graphs in Health Risk Communication: A Systematic Review
J. Am. Med. Inform. Assoc.,
November 1, 2006;
13(6):
608 - 618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Fagerlin, D. Rovner, S. Stableford, C. Jentoft, J. T. Wei, and M. Holmes-Rovner
Patient Education Materials about the Treatment of Early-Stage Prostate Cancer: A Critical Review
Ann Intern Med,
May 4, 2004;
140(9):
721 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L Fraenkel, S T Bogardus Jr, and D R Wittink
Risk-attitude and patient treatment preferences
Lupus,
May 1, 2003;
12(5):
370 - 376.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol.,
August 1, 2002;
20(15):
3328 - 3343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Schapira, A. B. Nattinger, and C. A. McHorney
Frequency or Probability? A Qualitative Study of Risk Communication Formats Used in Health Care
Med Decis Making,
December 1, 2001;
21(6):
459 - 467.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. Bogardus Jr, E. Holmboe, and J. F. Jekel
Perils, Pitfalls, and Possibilities in Talking About Medical Risk
JAMA,
March 17, 1999;
281(11):
1037 - 1041.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|